Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer
Cancer Medicine · 2023
DOI: 10.1002/cam4.5640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Zhi-Bin Ke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Abiraterone Acetate, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To investigate the predictive value of body composition parameters for biochemical response to abiraterone acetate (AA) in metastatic castration‐resistant prostate cancer (mCRPC) patients with prior chemohormonal therapy.
Methods
We retrospectively evaluated the clinicopathologic information of 132 mCRPC cases receiving AA treatment after chemohormonal therapy at hormone‐sensitive stage from July 2018 to June 2021. All patients were divided into AA responders and non‐responders according to the biochemical response to AA (prostate‐specific antigen (PSA) reduction ≥50% than pretreatment). Multivariate Logistic analysis was used to determine the independent predictors and develop predictive model of biochemical response to AA. Cox regression analysis was utilized to investigate the prognostic factors for time to biochemical progression (TTBP), radiological progression‐free survival (rPFS), failure‐free survival (FFS), and overall survival (OS) after AA treatment.
Results
There were 57 AA responders and 75 AA non‐responders. Periprostatic fat area/prostate area (PPFA/PA) was decreased and skeletal muscle index (SMI) was increased in AA responders compared with AA non‐responders. Multivariable logistic analysis demonstrated that ADT duration ≥12 months, bone metastasis only, high SMI and low PPFA/PA were independent predictors of biochemical response to AA treatment. The FFS, TTBP, rPFS, and OS of patients with lower SMI or higher PPFA/PA was decreased compared with that of patients with higher SMI or lower PPFA/PA, respectively. Combining SMI, PPFA/PA, ADT duration and metastatic sites performed well in differentiating AA responders from non‐responders.
Conclusions
High SMI and low PPFA/PA could predict biochemical response to AA treatment and preferable prognosis in mCRPC patients with prior chemohormonal therapy at hormone‐sensitive stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated, Fujian Medical University, Fuzhou, China.
- Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Yong Wei, Xue-Yi Xue, Ning Xu
Zitieren
APA
Ke, Z. B., You, Q., Xue, Y. T., Sun, J. B., Chen, J. Y., Liu, W. Q., Wei, Y., Zheng, Q. S., Li, X. D., Xue, X. Y., & Xu, N. (2023). Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer. Cancer Medicine. https://doi.org/10.1002/cam4.5640
Vancouver
Ke ZB, You Q, Xue YT, Sun JB, Chen JY, Liu WQ, et al. Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer. Cancer Medicine. 2023. doi:10.1002/cam4.5640
BibTeX
@article{Ke2023,
author = {Ke, Zhi-Bin and You, Qi and Xue, Yu-Ting and Sun, Jiang-Bo and Chen, Jia-Yin and Liu, Wen-Qi and Wei, Yong and Zheng, Qing-Shui and Li, Xiao-Dong and Xue, Xue-Yi and Xu, Ning},
title = {Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5640}
}
EUVIMED